Patch testing versus interferon-gamma release assay in evaluation of drug eruptions.
drug eruptions
interferon-gamma release assay
patch testing
Journal
Fundamental & clinical pharmacology
ISSN: 1472-8206
Titre abrégé: Fundam Clin Pharmacol
Pays: England
ID NLM: 8710411
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
revised:
06
09
2021
received:
18
04
2021
accepted:
17
10
2021
pubmed:
21
10
2021
medline:
16
3
2022
entrez:
20
10
2021
Statut:
ppublish
Résumé
Delayed-onset T-cell-mediated cutaneous adverse drug reactions are an uncommon but potentially serious result of medication exposures. Identification of culprit medications is crucial, but clinical diagnosis is often difficult. Patch tests and interferon-gamma release assays (IFNγ-RA) were previously reported as potentially useful ancillary tests, while rechallenges remain the reference standard test. We compared the number of positive test results with patch testing and IFNγ-RA for drugs implicated as possible causes of cutaneous reactions. Fifty-one patients with a suspected cutaneous drug eruption underwent patch testing and IFNγ-RA for suspected drugs. Participants were followed up at least 9 months after the onset of the rash with results compared with the clinical diagnosis. Forty-two patients presented with morbilliform/eczematous eruptions; five were diagnosed with fixed drug eruption (FDE) and four with erythema multiforme. None had positive patch testing to the drugs tested. A total of 8/51 (15.6%) patients had positive reaction by the IFNγ-RA, and an additional 11 (21.6%) patients had borderline results. Positive or borderline results were more likely in patients with FDE (80%) than morbilliform/eczematous eruptions (30.9%) or erythema multiforme (25%). Our study emphasizes the necessity of additional effective ancillary tests in the evaluation of drug eruptions and supports the use of IFNγ-RA for drug testing as a tool for identifying medications associated with cutaneous drug eruptions.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
414-420Informations de copyright
© 2021 Société Française de Pharmacologie et de Thérapeutique.
Références
Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol. 2001;137(6):765-770.
Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331(19):1272-1285.
Hunziker T, Künzi UP, Braunschweig S, Zehnder D, Hoigné R. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy. 1997;52(4):388-393.
Nigen S, Knowles SR, Shear NH. Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol. 2003;2(3):278-299.
Bircher AJ, Scherer K. Delayed cutaneous manifestations of drug hypersensitivity. Med Clin North am. 2010;94(4):711-725.
Duong TA, Valeyrie-Allanore L, Wolkenstein P, et al. Severe cutaneous adverse reactions to drugs. Lancet. 2017;390(10106):1996-2011.
Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57-65.
Lee AY. Fixed drug eruptions. Incidence, recognition, and avoidance. Am J Clin Dermatol. 2000;1(5):277-285.
Balakirski G, Merk HF. Cutaneous allergic drug reactions: update on pathophysiology, diagnostic procedures and differential diagnosic. Cutan Ocul Toxicol. 2017;36(4):307-316.
Schnyder B. Approach to the patient with drug allergy. Med Clin North am. 2010;94(4):665-679.
Samuelov L, Nathan A, Slutsky E, et al. Nested case-control study investigating the diagnostic role of tissue eosinophilia in adverse cutaneous drug reactions. J Eur Acad Dermatol Venereol. 2019;33(6):1152-1157.
Barbaud A, Collet E, Milpied B, et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol. 2013;168(3):555-562.
Barbaud A, Gonçalo M, Bruynzeel D, Bircher A, European Society of Contact Dermatitis. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Derm. 2001;45(6):321-328.
Brockow K, Garvey LH, Aberer W, et al. Skin test concentrations for systemically administered drugs-an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2013;68(6):702-712.
de Groot AC. Patch Testing: Test Concentrations and Vehicles for 4900 Chemicals. 4thed. Wapserveen, the Netherlands: acdegroot publishing; 2018.
Hassoun-Kheir N, Bergman R, Weltfriend S. The use of patch tests in the diagnosis of delayed hypersensitivity drug eruptions. Int J Dermatol. 2016;55(11):1219-1224.
Phillips EJ, Bigliardi P, Bircher AJ, et al. Controversies in drug allergy: testing for delayed reactions. J Allergy Clin Immunol. 2019;143(1):66-73.
Zinn Z, Gayam S, Chelliah MP, Honari G, Teng J. Patch testing for nonimmediate cutaneous adverse drug reactions. J am Acad Dermatol. 2018;78(2):421-423.
Goldberg I, Gilburd B, Shovman O, Brenner S. Clinical and laboratory assays in the diagnosis of cutaneous adverse drug reactions. Isr Med Assoc J. 2004;6(1):50-51.
Hertl M, Merk HF. Lymphocyte activation in cutaneous drug reactions. J Invest Dermatol. 1995;105(Suppl 1):95S-98S.
Trubiano JA, Strautins K, Redwood AJ, et al. The combined utility of ex vivo IFN-γ release enzyme-linked immunospot assay and in vivo skin testing in patients with antibiotic-associated severe cutaneous adverse reactions. J Allergy Clin Immunol Pract. 2018;6(4):1287-1296.
Goldberg I, Hanson M, Chodick G, Shirazi I, Brenner S. In vitro release of interferon-gamma from peripheral blood lymphocytes in cutaneous adverse drug reactions. Clin Dev Immunol. 2012;2012:687532-7.
Assier H, Valeyrie-Allanore L, Gener G, Verlinde Carvalh M, Chosidow O, Wolkenstein P. Patch testing in non-immediate cutaneous adverse drug reactions: value of extemporaneous patch tests. Contact Derm. 2017;77(5):297-302.
Halevy S, Cohen AD, Grossman N. Clinical implications of in vitro drug-induced interferon gamma release from peripheral blood lymphocytes in cutaneous adverse drug reactions. J am Acad Dermatol. 2005;52(2):254-261.